Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
129.86
+5.41 (4.35%)
At close: May 31, 2024, 4:00 PM
130.25
+0.39 (0.30%)
After-hours: May 31, 2024, 7:53 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for SRPT stock have an average target of 164.35, with a low estimate of 109 and a high estimate of 224. The average target predicts an increase of 26.56% from the current stock price of 129.86.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SRPT stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 7 | 6 |
| Buy | 9 | 9 | 9 | 8 | 8 | 7 |
| Hold | 3 | 3 | 3 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 19 | 19 | 18 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $157 | Buy | Initiates | $157 | +20.90% | May 31, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $157 → $142 | Buy → Hold | Downgrades | $157 → $142 | +9.35% | May 28, 2024 |
| Needham | Needham | Strong Buy Reiterates $166 | Strong Buy | Reiterates | $166 | +27.83% | May 20, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $145 → $179 | Strong Buy | Maintains | $145 → $179 | +37.84% | May 17, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $180 | Hold → Buy | Upgrades | $180 | +38.61% | May 14, 2024 |
Financial Forecast
Revenue This Year
1.97B
from 1.24B
Increased by 58.20%
Revenue Next Year
2.97B
from 1.97B
Increased by 50.99%
EPS This Year
3.68
from -5.80
EPS Next Year
11.81
from 3.68
Increased by 220.99%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.5B | 4.6B | 5.5B | 5.1B | 4.9B |
| Avg | 2.0B | 3.0B | 3.5B | 3.5B | 3.8B |
| Low | 1.6B | 1.8B | 1.6B | 2.3B | 2.4B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 104.0% | 134.8% | 85.0% | 48.4% | 42.5% |
| Avg | 58.2% | 51.0% | 16.5% | 0.3% | 8.4% |
| Low | 31.1% | -10.2% | -44.8% | -33.9% | -30.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.62 | 26.62 | 29.68 | 15.94 | 18.47 |
| Avg | 3.68 | 11.81 | 13.25 | 11.91 | 13.15 |
| Low | 0.88 | 1.30 | 0.74 | 8.20 | 9.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 623.5% | 151.4% | 20.3% | 55.0% |
| Avg | - | 221.0% | 12.2% | -10.1% | 10.4% |
| Low | - | -64.6% | -93.8% | -38.1% | -22.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.